• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Infection . Generation and persistence of S1 IgG and neutralizing antibodies in post-COVID-19 patients

tetano

Editor, Senior Moderator
Infection


. 2021 Oct 19.
doi: 10.1007/s15010-021-01705-7. Online ahead of print.
Generation and persistence of S1 IgG and neutralizing antibodies in post-COVID-19 patients


Oscar Guzmán-Martínez[SUP] #[/SUP][SUP] 1 2 [/SUP], Kathia Guardado[SUP] #[/SUP][SUP] 1 2 [/SUP], Miguel Varela-Cardoso[SUP] 3 [/SUP], Alejandro Trujillo-Rivera[SUP] 4 [/SUP], Antonio Marín-Hernández[SUP] 5 [/SUP], María Cristina Ortiz-León[SUP] 1 [/SUP], Iván Gómez-Ñañez[SUP] 1 [/SUP], Michelle Gutiérrez[SUP] 6 [/SUP], Rafaela Espinosa[SUP] 6 [/SUP], Clara Luz Sampieri[SUP] 1 [/SUP], Celso Ramos[SUP] 7 [/SUP], Delia Vanesa López-Guerrero[SUP] 8 [/SUP], Roberto Zenteno-Cuevas[SUP] 1 [/SUP], Julio Isael Pérez-Carreón[SUP] 9 [/SUP], Guadalupe Canales-Vázquez[SUP] 10 [/SUP], Hilda Montero[SUP] 11 [/SUP]



Affiliations

Abstract

Background: Antibody-mediated immune response plays an important role in protection against reinfection. In the case of SARS-CoV-2 infection, the maximum duration of antibody response is still unknown. In this work, the generation of neutralizing antibodies (NAbs) and IgG antibodies against the S1 subunit (S1 IgG ) of SARS-CoV-2 and their possible duration were determined through decay models.
Methods: 132 participants with SARS-CoV-2 infection were classified according to the severity of the disease. Seroconversion and persistence of S1 IgG antibodies and NAbs were determined by ELISA, samples were taken at two different times post-infection and duration of those antibodies was estimated using Linear Mixed Models (LMMs).
Results: The highest amount of S1 IgGs antibodies was associated with age (41 years or older), greater severity of COVID-19 and male gender. NAbs production was associated with the same variables, except for age. The percentage of NAbs decay is higher in the asymptomatic group (P = 0.033), while in S1 IgG antibodies decay, no statistical difference was found between the 4 severity groups. An exponential decay model was built by using a LMM and similarly, two dispersion regions where constructed. The duration of S1 IgG antibodies was 744 days (668-781) for first region and 744 days (453-1231) for the second. Regarding NAbs, an adaptative LMM was used to model a logistic function, determining a duration of 267 days (215-347).
Conclusion: Humoral immunity to SARS-CoV-2 infection depends on the severity of the disease, gender and age. This immune response could be long-lasting as for other coronaviruses.

Keywords: COVID-19; Neutralizing antibodies; SARS-CoV-2.
 
Back
Top Bottom